Eizen Joshua M, the Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc., recently sold 2,826 shares of the company’s common stock. This transaction, reported on November 6, 2026, was executed to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) on November 4, 2026.

This sale is significant as it highlights the active management decisions within the pharmaceutical preparations industry. Insider transactions can often influence investor confidence and market perceptions, making such disclosures critical for stakeholders.

Background

AN2 Therapeutics, Inc. is a company focused on developing innovative therapies in the pharmaceutical sector. The company is incorporated in Delaware and operates out of Menlo Park, California. It is classified under the Standard Industrial Classification (SIC) code for pharmaceutical preparations, which indicates its involvement in the development and commercialization of drugs.

The company’s recent filings include several Form 4 submissions, indicating ongoing insider transactions. The latest filing, dated November 6, 2026, follows previous filings on July 10, 2026, and March 23, 2026, among others.

What the Filing Says

The filing states that Eizen Joshua M sold 2,826 shares at a price of $4.22 per share. Following this transaction, he retains ownership of 207,546 shares of AN2 Therapeutics. The filing notes that the sale was necessary to cover tax obligations related to the vesting of RSUs.

“Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on November 4, 2026.”

Impact

This transaction may impact various stakeholders, including investors and analysts monitoring AN2 Therapeutics. Insider sales can signal to the market the financial health and future potential of the company. However, in this instance, the sale is framed within the context of tax obligations, which may mitigate concerns regarding the executive's confidence in the company’s stock.

What's Next

The filing does not say what happens next. However, as AN2 Therapeutics continues to navigate its operations and development projects, further insider transactions may be reported in the future, providing more insights into the company's management strategies.